Clinomic Revenue and Competitors
Estimated Revenue & Valuation
- Clinomic's estimated annual revenue is currently $22.3M per year.
- Clinomic's estimated revenue per employee is $251,000
Employee Data
- Clinomic has 89 Employees.
- Clinomic grew their employee count by 10% last year.
Clinomic's People
| Name | Title | Email/Phone |
|---|
Clinomic Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4M | 16 | 33% | N/A | N/A |
#2 | $90.4M | 288 | -7% | $773M | N/A |
#3 | $4M | 16 | -24% | N/A | N/A |
#4 | $1.3M | 5 | 0% | N/A | N/A |
#5 | $7.3M | 29 | 0% | N/A | N/A |
#6 | $89.6M | 357 | 28% | N/A | N/A |
#7 | $26.9M | 107 | -5% | N/A | N/A |
#8 | $3.3M | 13 | 30% | N/A | N/A |
#9 | $1.5M | 6 | -33% | N/A | N/A |
#10 | $28.4M | 113 | 12% | N/A | N/A |
What Is Clinomic?
Clinomic is a dynamic, fast-growing start-up focussed on developing innovative technological solutions for critically ill patients. We create groundbreaking solutions for the critically ill by combining translational medical research, data science and computational intelligence. With a patient-centric view, we combine state-of-the-art research with modern technologies to enable an optimal treatment for every patient. Legal : https://www.clinomic.ai/imprint/ Privacy: https://www.clinomic.ai/data-privacy/
keywords:N/A
N/A
Total Funding
89
Number of Employees
$22.3M
Revenue (est)
10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Clinomic News
Evolucare, Clinomic, Ascom, PICIS, GE Healthcare, Mela Solutions, NEXUS AG, Philips NV, Bow Medical, iMDsoft.
Clinomic Gmbh · Czech Academy of Sciences · Emovo Care Sa · Iit-G · Imito Ag · Kth Royal Institute of Technology · Medkitdoc.
Other Companies in Aachen
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $29M | 90 | 50% | N/A |
#2 | $21.8M | 99 | 36% | N/A |
#3 | $37M | 118 | 26% | $109M |
#4 | $42.6M | 129 | -12% | N/A |
#5 | $19.4M | 134 | 12% | N/A |